Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making

In the past few years, we have seen the emergence of numerous biologics on the market for severe type 2 (T2) asthma. In addition to omalizumab (a monoclonal anti-IgE antibody), three anti-interleukin (IL) 5 agents are approved for eosinophilic asthma and an anti-IL4Ra biologic recently received FDA approval for the indication of severe asthma. For patients with severe T2 asthma (about 5% of the asthma population), this translates to newer, targeted therapeutic options that have been shown to reduce asthma exacerbations and that generally have a favorable side effect profile(1).

Source: Annals of Allergy, Asthma and Immunology - July 23, 2019 Category: Allergy & Immunology Authors: Mauli Desai, John Oppenheimer Tags: Perspective Source Type: research